Compounds specific to coronavirus S protein and uses thereof
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure include the use of anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
1. A method of treating an infection of a subject by a coronavirus, the method comprising administering to the subject an antibody, or antigen-binding fragment thereof, which binds to a spike protein of the coronavirus, wherein the antibody, or antigen-binding fragment thereof, comprises
a heavy chain variable region (VH) comprising a VH complementarity-determining region 1 (CDR1) comprising SEQ ID NO:22304, a VH complementarity-determining region 2 (CDR2) comprising SEQ ID NO:22306, and a VH complementarity-determining region 3 (CDR3) comprising SEQ ID NO:22308; and
a light chain variable region (VL) comprising a VL CDR1 comprising SEQ ID NO:22314, a VL CDR2 comprising SEQ ID NO:22316, and a VL CDR3 comprising SEQ ID NO:22318.
2. The method of claim 1 , wherein the VH comprises SEQ ID NO:22302 and the VL comprises SEQ ID NO:22312.
3. The method of claim 2 , wherein the VH consists of SEQ ID NO:22302 and the VL consists of SEQ ID NO:22312.
4. The method of claim 1 , wherein the subject is a human subject.
5. The method of claim 1 , wherein the subject has at least one risk factor which renders them more prone to a poor clinical outcome.
6. The method of claim 5 , wherein the at least one risk factor is selected from the group consisting of: an old age selected from the group consisting of over 55, over 60 or over 65 years old; diabetes; a chronic respiratory condition; obesity; hypertension; a cardiac or cardiovascular condition; a chronic inflammatory or autoimmune condition; and an immune compromised status.
7. The method of claim 1 , wherein the antibody, or the antigen-binding fragment thereof, is administered intramuscularly or intravenously.
8. The method of claim 1 , wherein the antibody, or the antigen-binding fragment thereof, is administered at a dose of 300 mg to 1200 mg.
9. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, is administered once or is administered weekly.
10. The method of claim 1 , wherein the method further comprises administering a second antibody, or second antigen-binding fragment thereof, wherein the second antibody, or second antigen-binding fragment thereof, comprises VH comprising a VH CDR1 comprising SEQ ID NO:21904, a VH CDR2 comprising SEQ ID NO:21906, and a VH CDR3 comprising SEQ ID NO:21908, and a VL comprising a VL CDR1 comprising SEQ ID NO:21914, a VL CDR2 comprising SEQ ID NO:21916, and a VL CDR3 comprising SEQ ID NO:21918.
11. The method of claim 10 , wherein the VH of the second antibody, or second antigen-binding fragment thereof, comprises SEQ ID NO:21902 and wherein the VL of the second antibody, or second antigen-binding fragment thereof, comprises SEQ ID NO:21912.
12. The method of claim 11 , wherein the VH of the second antibody, or second antigen-binding fragment thereof, consists of SEQ ID NO:21902 and wherein the VL of the second antibody, or second antigen-binding fragment thereof, consists SEQ ID NO:21912.
13. The method of claim 1 , wherein the coronavirus is SARS-CoV or SARS-CoV-2.